A phase I dose escalation study using HER2-specific CAR T cells derived from virus-specific T cells (VST) in 17 GBM patients demonstrated only limited clinical efficacy with a median OS of 11.1 months, and lack of durable expansion of HER2-specific CAR VST in the peripheral blood [110]. The gene discussed is ERBB2; the disease is glioblastoma.